Pangram verdict · v3.3
We believe that this document is fully human-written
AI likelihood · overall
HumanArticle text · 826 words · 6 segments analyzed
Info
Poster Board Number: 279
Background:SARS-CoV-2 RNA can persist in tissues long after initial infection, but with unclear significance. After acute illness, some patients experience persistent symptoms of potential cardiac origin, such as palpitations, chest pain, shortness of breath, and fatigue consistent with cardiac Long COVID (CLC). Cardiac viral persistence may drive CLC symptoms and could have direct implications for patient care. We investigated whether the presence of SARS-CoV-2 reverse strand, a marker of viral replication, in the left ventricle (LV) is associated with CLC, pathologic changes and altered gene expression.
Design:We studied 74 decedents ≥60 days from initial infection, who underwent expedited autopsy. Cardiac LV tissue was subjected to transcriptomic analysis using NanoString nCounter® HOT Panel / Coronavirus Panel Plus. Viral positivity was defined as detection of reverse strand relative to negative controls, and its associations with clinical and pathologic features were determined. Differential gene expression (DGE) analysis was performed comparing patients with (V+) and without (V-) SARS-CoV-2 reverse strand. Immunohistochemistry (IHC) for IRF4 and in-situ hybridization (ISH) for viral spike gene positive strand were performed.
Results:Of 74 cases, 11 were V+ and 63 were V-. There was no significant difference in demographics, comorbidities, cause of death, initial viral variant, interval from initial infection, vaccination status, and presence of myocarditis. CLC was seen in 9 (82%) of 11 V+ cases and 23 (37%) of 63 V- cases (p=0.0075). V+ cases had a shorter interval from last positive swab (median 299 vs 522 days; p=0.01) and a higher prevalence of severe acute COVID-19 (30% vs 3%; p=0.02).
V+ hearts showed higher heart-weight-to-LV-wall-thickness ratios (mean 437 vs 340 g/cm; p=0.005), more frequent LV dilatation (64% vs 24%, p=0.01), and more frequent pericardial fluid ≥30 mL (40% vs 14%; p=0.048). SARS-CoV-2 ISH was positive in cardiac myocytes in V+ cases. DGE analysis showed significant alteration in the expression of 44 genes involved in inflammation and host response, particularly interferon regulatory factor 4 (IRF4). By IHC, IRF4+ cells were seen mainly in the epicardium.
Figure 1:
Click to view full size Figure 2:
Click to view full size Conclusion:Detection of SARS-CoV-2 reverse strand in the hearts of a subset of patients with CLC provides molecular evidence of viral persistence that may drive the structural and immune changes underlying their symptoms, offering mechanistic insights that could inform new diagnostic and therapeutic strategies.
Disclosures:
Faye Victoria Casimero: None; Aram Krauson: None; Pritha Sen: None; David Milstone: None; Maria Martinez-Lage: None; Robert Padera: Consultant - Morair; Vergent; Vanessa Hannay: None; Zakir Siddiquee: None; Iris Lopez: None; Mayara Bearse: None; Andrea Troxel: Other - BioAge; Cellectis; Carolyn Glass: None; Thomas Flotte: None; Michelle Lamendola-Essel: None; Chloe Young: None; Phoebe Del Boccio: None; Paul Benson: None; Jonathan Melamed: None; Avi Rosenberg: None; Silvio Litovsky: None; Richard Moffitt: None; Dezhi Wang: None; Vivian Gainer: None; Ayat Abdelsalam: None; Elizabeth Handel: None; Ben White: None; Ameera Afifi: None; James Stone: None
Authors
Faye
Victoria C. Casimero, MD Massachusetts General Hospital, Harvard Medical School Medford, MA, United States
Aram J. Krauson, PhD Massachusetts General Hospital Charlestown, MA, United States
Pritha Sen, MD Brigham and Women's Hospital Boston, MA, United States
David S. Milstone, MD, PhD Brigham and Women's Hospital Boston, MA, United States
Maria Martinez-Lage, MD Mass General Brigham Boston, MA, United States
Robert Padera, MD, PhD Brigham and Women's Hospital Boston, MA, United States
Vanessa Hannay, MS Massachusetts General Hospital Charlestown, MA, United States
Zakir Siddiquee, N/A Massachusetts General Hospital Cambridge, MA, United States
Iris A. Lopez,
BA Massachusetts General Hospital Cambridge, MA, United States
Mayara Bearse, MD Cedars-Sinai Medical Center Beverly Hills, CA, United States
Andrea B. Troxel, ScD New York University Langone Health New York, NY, United States
Carolyn Glass, MD, PhD Duke University Medical Center Durham, NC, United States
Thomas J. Flotte, MD Mayo Clinic Faribault, MN, United States
Michelle F. Lamendola-Essel, DHSc New York University Langone Health Port Jefferson Station, NY, United States
Chloe E. Young, BS New York University Langone Health Ridgewood, NJ, United States
Phoebe Del Boccio, PhD, MSc New York University Langone Health Montclair, NJ, United States
Paul
Vincentin Benson, MD The University of Alabama at Birmingham Birmingham, AL, United States
Jonathan Melamed, MD New York University Long Island Mineola, NY, United States
Avi Z. Rosenberg, MD, PhD Johns Hopkins University School of Medicine Baltimore, MD, United States
Silvio H. Litovsky, MD The University of Alabama at Birmingham Birmingham, AL, United States
Richard A. Moffitt, PhD Emory University School of Medicine Atlanta, GA, United States
Dezhi Wang, MD, MBA The University of Alabama at Birmingham Birmingham, AL, United States
Vivian S. Gainer, MS Mass General Brigham Somerville, MA, United States
Ayat Abdelsalam, MD The University of Alabama at Birmingham Vestavia hills, AL, United States
Elizabeth A. Handel, BS Duke University Pittsboro, NC, United States
Ben White, N/A My Institution Is Not Listed deerfield, IL, United States
Ameera Afifi, BS, BA Duke University Durham, NC, NC, United States
James R. Stone, MD, PhD Massachusetts General Hospital Charlestown, MA, United States